BRAF and MET+ NSCLC patients seem to derive more benefit than some other oncogene-addicted NSCLCs from ICIs, however, this seems to be less than KRASm or non-oncogene-addicted NSCLCs, and treatment with additional chemotherapy may be appropriate, even in those with high PDL-1 expression, to offset this concern. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.